TOP TEN perturbations for 39704_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39704_s_at
Selected probe(set): 206074_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39704_s_at (206074_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
SDF study 4 / untreated MDA Mb231 cell sample
Relative Expression (log2-ratio):-4.4087076Number of Samples:3 / 6
Experimental | SDF study 4 |
MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h. | |
Control | untreated MDA Mb231 cell sample |
Untreated MDA Mb231 cells harvested after 6h. |
ovarian tumor study 14 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):3.8432055Number of Samples:4 / 4
Experimental | ovarian tumor study 14 |
Human pooled cancer samples from the ovary of patients with moderate and poorly differentiated serous carcinoma of the ovary. | |
Control | normal ovarian surface epithelial cell sample |
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases. |
Hep-G2 / HepaRG
Relative Expression (log2-ratio):3.707882Number of Samples:9 / 12
Experimental | Hep-G2 |
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: | |
Control | HepaRG |
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):3.6183395Number of Samples:2 / 2
Experimental | T-cell activation study 4 |
T-cell samples antiCD3 activated for 30hrs. | |
Control | normal resting T-cell sample |
T cells resting for 30h. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Relative Expression (log2-ratio):-3.4994478Number of Samples:2 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
stem cell differentiation study 47 (BMP-2; TGFb; 7d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):-3.4415693Number of Samples:3 / 6
Experimental | stem cell differentiation study 47 (BMP-2; TGFb; 7d) |
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
Control | stem cell differentiation study 47 (0d) |
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
stem cell differentiation study 47 (BMP-2; 7d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):-3.3681593Number of Samples:3 / 6
Experimental | stem cell differentiation study 47 (BMP-2; 7d) |
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
Control | stem cell differentiation study 47 (0d) |
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Relative Expression (log2-ratio):-3.2808323Number of Samples:3 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (endometrioid carcinoma; metastatic)
Relative Expression (log2-ratio):-3.2686129Number of Samples:2 / 3
Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
Control | expO ovary cancer study 1 (endometrioid carcinoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary. |
HCC study 9 (HBV; HCV) / normal liver tissue
Relative Expression (log2-ratio):3.255415Number of Samples:2 / 10
Experimental | HCC study 9 (HBV; HCV) |
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection. | |
Control | normal liver tissue |
Normal, non-tumor liver tissue. |